Absence of p53 complements defects in Abelson murine leukemia virus signaling

Journal of Virology

Volumn 77, Issue 11, 2003, Pages 6208-6215

  Unnikrishnan, Indira ^a,b   Rosenberg, Naomi ^a  

^a TUFTS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b THOMAS JEFFERSON UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ABELSON KINASE; ARF PROTEIN; GENE PRODUCT; PROTEIN P53; UNCLASSIFIED DRUG; VIRUS PROTEIN;

ABELSON MURINE LEUKEMIA ONCOVIRUS; ANIMAL CELL; ARTICLE; CELL PROLIFERATION; GENE; GENE LOCUS; GENE MUTATION; HYPOTHESIS; INK4A GENE; MOUSE; NONHUMAN; NULL ALLELE; PRE B LYMPHOCYTE; PREDICTION; PRIORITY JOURNAL; PROTEIN DEFECT; SIGNAL TRANSDUCTION; TUMOR SUPPRESSOR GENE; VIRUS CELL TRANSFORMATION; VIRUS TRANSFORMATION; WILD TYPE;

3T3 CELLS; ABELSON MURINE LEUKEMIA VIRUS; ANIMALS; APOPTOSIS; B-LYMPHOCYTES; CELL LINE; CELL LINE, TRANSFORMED; CELL TRANSFORMATION, VIRAL; HUMANS; MICE; MUTATION; ONCOGENE PROTEINS V-ABL; SIGNAL TRANSDUCTION; SRC HOMOLOGY DOMAINS; TEMPERATURE; TUMOR SUPPRESSOR PROTEIN P53;

EID: 0037689280     PISSN: 0022538X     EISSN: None     Source Type: Journal    
DOI: 10.1128/JVI.77.11.6208-6215.2003     Document Type: Article

References (37)

1. Bradshaw, J. M., V. Mitaxov, and G. Waksman. 1999. Investigation of phosphotyrosine recognition by the SH2 domain of the Src kinase. J. Mol. Biol. 293:971-985.
2. Bradshaw, J. M., V. Mitaxov, and G. Waksman. 2000. Mutational investigation of the specificity determining region of the Src SH2 domain. J. Mol. Biol. 299:521-535.
3. t. Proc. Natl. Acad. Sci. USA 89:6683-6687.
4. Chen, Y.-Y., L. C. Wang, M. S. Huang, and N. Rosenberg. 1994. An active v-abl protein tyrosine kinase blocks immunoglobutin tight-chain gene rearrangement. Genes Dev. 8:688-697.
5. Danial, N. N., and P. Rothman. 2000. JAK-STAT signaling activated by Abl oncogenes. Oncogene 19:2523-2531.
6. ARF tumor suppressor. Genes Dev. 12:2434-2442.
7. DuBridge, R. B., P. Tang, H. C. Hsai, P.-M. Leong, J. H. Miller, and M. P. Calos. 1987. Analysis of mutation in human cells by using an Epstein-Barr virus shuttle system. Mol. Cell. Biol. 7:379-387.
8. Engelman, A., and N. Rosenberg. 1990. bcr/abl and src but not myc and ras replace v-abl in lymphoid transformation. Mol. Cell. Biol. 10:4365-4369.
9. Engelman, A., and N. Rosenberg. 1990. Temperature-sensitive mutants of Abelson murine leukemia virus deficient in protein tyrosine kinase activity. J. Virol. 64:4242-4251.
10. Green, P. L., D. A. Kaehler, and R. Risser. 1987. Clonal dominance and progression in Abelson murine leukemia virus lymphomagenesis. J. Virol. 61:2192-2197.
11. Hawley, R. G., F. H. Lieu, A. Z. Fong, and T. S. Hawley. 1994. Versatile retroviral vectors for potential use in gene therapy. Gene Ther. 1:136-138.
12. Jenab-Wolcott, J., D. Rodriguez-Correa, A. Reitmair, T. Mak, and N. Rosenberg. 2000. The absence of Msh2 alters Abelson virus pre-B-cell transformation by influencing p53 mutation. Mol. Cell. Biol. 20:8373-8381.
13. Mainville, C., K. Parmar, I. Unnikrishnan, G. D. Raffel, L. Gong, and N. Rosenberg. 2001. Alteration of the FLVRES motif in the v-Abl SH2 domain confers a temperature-sensitive transformation phenotype. J. Virol. 75:1816-1823.
14. Mayer, B. J., and D. Baltimore. 1994. Mutagenic analysis of the roles of SH2 and SH3 domains in regulation of the Abl tyrosine kinase. Mol. Cell. Biol. 14:2883-2894.
15. Mayer, B. J., P. K. Jackson, R. A. Van Etten, and D. Baltimore. 1992. Point mutations in the abl SH2 domain coordinately impair phosphotyrosine binding in vitro and transforming activity in vivo. Mol. Cell. Biol. 12:609-618.
16. Mayo, L. D., and D. B. Donner. 2001. A phosphatidylinositol 3-kinase/Akt phosphorylation pathway promotes translocation of Mdm2 from the cytoplasm to the nucleus. Proc. Natl. Acad. Sci. USA 98:11598-11603.
17. Muller, A. J., J. C. Young, A. M. Pendergast, M. Pondel, D. R. Litman, and O. N. Witte. 1991. BCR first exon sequences specifically activates the BCR/ABL tyrosine kinase oncogene of Philadelphia chromosome-positive human leukemias. Mol. Cell. Biol. 11:1785-1792.
18. Arf induces p53-dependent apoptosis during Abelson virus-mediated pre-B cell transformation. Proc. Natl. Acad. Sci. USA 95:13194-13199.
19. Reid, S., R. Cross, and E. Snow. 1996. Combined Hoechst 33342 and merocyanin 540 staining to examine murine B cell cycle stage, viability and apoptosis. J. Immunol. Methods 192:43-54.
20. Rosenberg, N., and D. Baltimore. 1976. A quantitative assay for transformation of bone marrow cells by Abelson murine leukemia virus. J. Exp. Med. 143:1453-1463.
21. Rosenberg, N., and O. N. Witte. 1988. The viral and cellular forms of the Abelson (abl) oncogene. Adv. Virus Res. 35:39-81.
22. Sawyers, C. L., W. Callahan, and O. N. Witte. 1992. Dominant negative myc blocks transformation by abl oncogenes. Cell 70:901-910.
23. Sawyers, C. L., J. McLaughlin, and O. N. Witte. 1995. Genetic requirement for ras in the transformation of fibroblasts and hematopoietic cells by the bcr-abl oncogene. J. Exp. Med. 181:307-313.
24. Sherr, C. J. 2001. The Ink4a/ARF network in tumour suppression. Nat. Rev. Mol. Cell Biol. 2:731-737.
25. Skorski, T., A. Bellacosa, M. Nieborowska-Skorska, M. Majewski, R. Martinez, J. K. Choi, R. Trotta, P. Wlodarski, D. Perrotti, T. O. Chan, M. A. Wasik, P. N. Tsichlis, and B. Calabretta. 1997. Transformation of hematopoietic cells by BCR/ABL requires activation of a PI-3K/Akt-dependent pathway. EMBO J. 16:6151-6161.
26. Thome, K., A. Radfar, and N. Rosenberg. 1997. Mutation of Tp53 contributes to the malignant phenotype of Abelson virus-transformed lymphoid cells. J. Virol. 77:8149-8156.
27. Unnikrishnan, I., A. Radfar, J. Jenab-Wolcott, and N. Rosenberg. 1999. p53 mediates apoptotic crisis in primary. Abelson-transformed pre-B cells. Mol. Cell. Biol. 19:4825-4831.
28. Van Parijs, L., Y. Refaeli, J. D. Lord, B. H. Nelson, A. K. Abbas, and D. Baltimore. 1999. Uncoupling IL-2 signals that regulate T cell proliferation, survival, and Fas-mediated activation induced cell death. Immunity 11:281-288.
29. Wahl, G. M., and A. M. Carr. 2001. The evolution of diverse biological responses to DNA damage: insights from yeast and p53. Nat. Cell Biol. 3:E277-E286.
30. Warren, D., D. S. Griffin, C. Mainville, and N. Rosenberg. 2003. The extreme carboxyl terminus of v-Abl is required for lymphoid cell transformation by Abelson virus. J. Virol. 77:4617-4625.
31. Warren, D., A. J. Heilpern, K. Berg, and N. Rosenberg. 2000. The carboxyl terminus of v-Abl protein can augment SH2 domain function. J. Virol. 74:4495-4504.
32. Whitlock, C. A., and O. N. Witte. 1981. Abelson virus-infected cells exhibit restricted in vitro growth and low oncogenic potential. J. Virol. 40:577-584.
33. Whitlock, C. A., S. F. Ziegler, and O. N. Witte. 1983. Progression of the transformed phenotype in clonal lines of Abelson virus-infected lymphocytes. Mol. Cell. Biol. 3:596-604.
34. Zhou, B. P., A. Liao, W. Xia, Y. R. Zou, B. Spohn, and M. C. Hung. 2001. HER-2/neu induces p53 ubiquitination via Akt-mediated MDM2 phosphorylation. Nat. Cell Biol. 3:973-982.
35. Zindy, F., C. M. Eischen, D. H. Randle, T. Kamijo, J. L. Cleveland, C. J. Sherr, and M. F. Roussel. 1998. Myc signaling via the ARF tumor suppressor regulates p53-dependent apoptosis and immortalization. Genes Dev. 12:2424-2433.
36. Zou, X., F. Cong, M. Coutts, G. Cattoretti, S. P. Goff, and K. Calame. 2000. p53 deficiency increases transformation by v-Abl and rescues the ability of a C-terminally truncated v-Abl mutant to induce pre-B lymphoma in vivo. Mol. Cell. Biol. 20:628-633.
37. Zou, X., S. Rudchenko, K.-K. Wong, and K. Calame. 1997. Induction of c-myc transcription by the v-Abl tyrosine kinase requires Ras, Rafl, and cyclin-dependent kinases. Genes Dev. 11:654-662.